Last updated: October 30, 2026
ProstaScint, or capromab pendetide labeled with indium In-111, is a discontinued prostate-cancer imaging agent. Its commercial decline reflected limited diagnostic performance, competition from conventional imaging and newer prostate-specific membrane antigen (PSMA) technologies, manufacturing and supply constraints, and the failure of the product to establish a durable clinical niche. Public disclosures indicate that ProstaScint generated meaningful revenue for Cytogen in the late 2000s, but sales declined before the product left the market.
What was ProstaScint and what did it treat?
ProstaScint was a radiolabeled monoclonal antibody imaging product used to detect prostate cancer in soft tissue, particularly suspected pelvic lymph-node or extra-prostatic disease. The active antibody, capromab, targeted an intracellular epitope of PSMA. The product was supplied as a kit and radiolabeled with indium In-111 before administration.
The FDA approved ProstaScint in 1996 under NDA 20-642. Its labeled use was adjunctive imaging in patients with biopsy-proven prostate cancer who were at high risk for pelvic lymph-node metastases or recurrent disease after treatment.[1]
| Product characteristic |
ProstaScint |
| Active agent |
Capromab pendetide |
| Radiolabel |
Indium In-111 |
| Target |
PSMA-associated intracellular epitope |
| Dosage form |
Radiolabeled diagnostic imaging kit |
| Initial sponsor |
Cytogen Corp. |
| FDA approval |
1996 |
| FDA application |
NDA 20-642 |
| Current commercial status |
Discontinued |
| Therapeutic category |
Nuclear medicine oncology diagnostic |
| Biosimilar relevance |
None in the conventional therapeutic sense |
ProstaScint was not a therapeutic prostate-cancer drug. It did not treat tumors, reduce prostate-specific antigen levels, or improve survival. Its commercial value depended on whether imaging changed surgical, radiation, or systemic-treatment decisions.
When did ProstaScint lose exclusivity and market protection?
ProstaScint's regulatory exclusivity expired many years before commercial discontinuation. The product was approved in 1996, so any standard new chemical entity exclusivity associated with the approval would have ended by approximately 2001. The product's practical protection therefore depended on patents, manufacturing know-how, radiolabeling logistics, physician adoption, and the absence of competitive alternatives.
ProstaScint is not a current Orange Book growth asset. FDA records identify the NDA as discontinued, and no active market position remains comparable to a currently marketed branded oncology product.[2]
What patents protected ProstaScint?
Publicly available FDA and company materials do not establish a current, commercially enforceable ProstaScint patent estate. The product was introduced more than 25 years ago, making any foundational composition or antibody patents likely expired under the applicable patent term rules.
The relevant intellectual-property categories would have included:
- The capromab antibody and antibody-producing cell line.
- The antibody's binding characteristics and PSMA-related epitope.
- Conjugation of the antibody to a chelating agent.
- Radiolabeling with indium In-111.
- Kit composition, storage, preparation, and quality-control methods.
- Imaging methods for prostate-cancer staging or recurrence.
Patent expiration would not have removed all barriers to competition. A substitute product would still have required clinical validation, radiopharmacy manufacturing, FDA approval, and reliable distribution through nuclear-medicine facilities.
How did ProstaScint's financial trajectory develop?
Cytogen's public filings show that ProstaScint was a material commercial product before its decline. The company marketed ProstaScint alongside Quadramet, another oncology radiopharmaceutical. Cytogen reported declining product revenue as physician use weakened and the prostate-imaging market moved toward more familiar and clinically integrated diagnostic approaches.[3]
The financial trajectory had four stages:
| Period |
Financial and commercial position |
| 1996-early 2000s |
Product launch and initial adoption in high-risk prostate-cancer staging |
| Mid-2000s |
Established niche product, but dependent on specialist use and nuclear-medicine infrastructure |
| Late 2000s-early 2010s |
Declining revenue, lower utilization, and increasing competitive pressure |
| After discontinuation |
No recurring branded-product revenue from ProstaScint |
Cytogen's filings grouped product sales and did not always provide a complete, standalone ProstaScint revenue history. The disclosures nevertheless show that the product was no longer a growth engine by the end of the 2000s. Revenue concentration in a small number of nuclear-medicine products increased the commercial impact of declining ProstaScint demand.
The product's economic model had structural weaknesses:
- It required a specialized radiolabeling and imaging workflow.
- It imposed scheduling constraints because of the radioactive isotope.
- It depended on trained nuclear-medicine personnel.
- Its clinical interpretation was difficult relative to standard anatomic imaging.
- Reimbursement and physician adoption were sensitive to evidence of incremental clinical value.
Why did ProstaScint sales decline?
The central market problem was diagnostic performance. ProstaScint targeted an intracellular PSMA epitope that was less accessible in viable tumor cells than extracellular PSMA targets used by newer agents. This limited sensitivity and created interpretation challenges.
How did ProstaScint compare with competing imaging?
Before PSMA-targeted positron emission tomography became commercially available, clinicians could use combinations of pelvic MRI, CT, bone scans, transrectal ultrasound, biopsy, and clinical risk scores. These approaches had limitations, but they were familiar, widely available, and integrated into existing treatment pathways.
| Technology |
Main advantage over ProstaScint |
Commercial limitation |
| Pelvic MRI |
Better anatomic assessment of local disease |
Variable availability and interpretation |
| CT |
Broad availability and lower workflow complexity |
Limited sensitivity for small-volume nodal disease |
| Bone scan |
Established assessment of osseous metastases |
Weak for soft-tissue disease |
| Choline PET |
More favorable whole-body functional imaging in some settings |
Limited adoption and access |
| PSMA PET |
Higher target specificity and strong clinical adoption |
Isotope supply, reimbursement, and facility requirements |
| ProstaScint |
Early PSMA-directed molecular imaging |
Lower sensitivity, complex imaging, limited clinical utility |
The product's position deteriorated as clinicians gained access to imaging methods that delivered clearer staging information. ProstaScint also suffered from the absence of a broad treatment-selection role. A diagnostic agent is commercially stronger when its result directly determines a reimbursed intervention or identifies patients for a specific therapy.
What was the FDA regulatory status of ProstaScint?
ProstaScint was FDA-approved but is no longer marketed. The product's regulatory history is distinct from that of modern PSMA PET agents.
The FDA approved ProstaScint as an indium In-111 radiolabeled antibody imaging product in 1996. Current prostate-cancer imaging has shifted toward PSMA PET agents, including gallium Ga-68 and fluorine F-18 products. These newer agents use different antibodies or small-molecule ligands and are approved through separate regulatory applications.
ProstaScint was not a biosimilar reference product. A future developer would not ordinarily pursue a standard therapeutic biosimilar pathway for a discontinued diagnostic radiopharmaceutical. A replacement would more likely require an independent application supported by analytical, imaging, safety, and clinical data.
What generic entry risks existed for ProstaScint?
There is no active generic-entry event comparable to a Paragraph IV challenge against a major marketed drug. ProstaScint's commercial exit occurred through market discontinuation rather than a visible generic launch.
A competing developer could theoretically pursue:
- A 505(b)(2) application for a similar radiolabeled antibody product.
- A new drug application for a distinct PSMA imaging agent.
- A radiopharmaceutical application based on a different ligand or isotope.
- A contract-manufactured diagnostic kit using comparable antibody technology.
The practical risk was therefore substitution, not conventional generic erosion. New imaging technologies displaced ProstaScint without needing to replicate its formulation exactly.
Which companies challenged ProstaScint's market position?
The main competitive challenge came from technology categories rather than a single direct generic manufacturer.
Conventional imaging providers
Hospitals and imaging centers using CT, MRI, bone scans, and biopsy-based staging reduced the need for ProstaScint. These alternatives were already embedded in urology and oncology workflows.
PSMA imaging developers
Later entrants commercialized PSMA-targeted PET products with stronger clinical performance and better integration into recurrence and metastatic-disease management. Notable companies in the broader PSMA imaging market include Telix, Novartis, Blue Earth Diagnostics, and other radiopharmaceutical developers. Their products did not necessarily compete with ProstaScint during its peak sales period, but they made the older technology commercially obsolete.
Contract manufacturers and radiopharmacies
ProstaScint required specialized production, quality control, isotope handling, and time-sensitive distribution. A disruption at any point in that chain could affect hospital use. This manufacturing burden reduced the product's resilience relative to imaging modalities based on standard MRI or CT infrastructure.
What litigation and settlement agreements affected ProstaScint?
No major current patent-litigation campaign or Paragraph IV settlement defines the ProstaScint market. The product's key commercial issues were adoption, evidence, supply, reimbursement, and competition from newer imaging methods.
Because the product is discontinued, there is no active branded-generic settlement framework that materially affects launch timing. Any historical patent disputes would need to be evaluated against the specific patent, jurisdiction, asserted claims, and date of litigation. They do not create a current commercial barrier comparable to active litigation involving a marketed prostate-cancer therapy.
How strong was the ProstaScint patent estate?
The estate is commercially weak today because the product is discontinued and its earliest technology dates to the 1990s. Patent protection, even where it once existed, cannot preserve demand when clinical utility has declined.
Its historical strengths likely included:
- First-mover positioning in antibody-based prostate-cancer imaging.
- Specialized antibody and radiolabeling know-how.
- Regulatory data supporting the approved indication.
- Manufacturing and distribution experience in nuclear medicine.
Its weaknesses included:
- Limited target accessibility.
- Dependence on a narrow imaging indication.
- Lack of a therapeutic companion product.
- Short clinical half-life as newer PSMA imaging technologies emerged.
- Complex logistics involving indium In-111 and nuclear-medicine facilities.
What was the revenue exposure for Cytogen and later owners?
ProstaScint was commercially important to Cytogen because the company's portfolio was concentrated in specialty oncology and radiopharmaceutical products. A decline in ProstaScint sales had a disproportionate effect on total product revenue compared with a diversified pharmaceutical company that could absorb one declining brand.
Cytogen's filings described declining demand and product-related operating pressure during the period before its corporate transition. The company ultimately became part of a broader specialty-pharmaceutical structure, but ProstaScint did not regain commercial momentum.[3]
The revenue exposure was greatest in:
- Nuclear-medicine product sales.
- Specialty oncology distribution.
- Radiopharmacy relationships.
- Sales infrastructure supporting prostate-cancer imaging.
- Manufacturing capacity tied to a low-volume diagnostic product.
After discontinuation, ProstaScint had no meaningful contribution to recurring revenue. Its residual economic value was limited to historical know-how, regulatory records, and potential licensing relevance for antibody-based imaging technology.
What generic launch scenarios existed?
Three scenarios were theoretically possible:
- A direct capromab pendetide replacement could seek approval, but the weak clinical position would make development unattractive.
- A reformulated or differently labeled antibody product could pursue an independent regulatory pathway, but clinical differentiation would be difficult.
- A next-generation PSMA PET agent could replace the product without relying on its patents or formulation.
The third scenario occurred at the market level. New PSMA imaging agents addressed the same broad diagnostic need with better-performing technologies and more relevant clinical use cases.
Key Takeaways
- ProstaScint was an FDA-approved indium In-111 capromab pendetide imaging agent introduced in 1996.
- Its commercial decline preceded discontinuation and reflected limited diagnostic performance, workflow complexity, and competition from MRI, CT, bone imaging, and newer PSMA PET technologies.
- Cytogen's public filings show that ProstaScint was a meaningful but declining revenue product in the late 2000s.
- No current Orange Book exclusivity, Paragraph IV challenge, biosimilar pathway, or major patent-litigation campaign drives the product's market.
- The main competitive threat was technology substitution rather than generic launch.
- ProstaScint has no meaningful current revenue trajectory or commercial launch opportunity based on its historical product profile.
- Any residual value lies in historical antibody, radiolabeling, manufacturing, or regulatory know-how, not in active branded sales.
FAQs
Is ProstaScint still available in the United States?
No. ProstaScint is listed as discontinued and is not an active commercial prostate-cancer imaging product.
What is the active ingredient in ProstaScint?
The active antibody is capromab pendetide, radiolabeled with indium In-111 before administration.
Was ProstaScint a PSMA PET scan?
No. ProstaScint was an antibody-based single-photon emission computed tomography imaging product using indium In-111. Modern PSMA PET agents generally use different ligands and positron-emitting isotopes.
Could a company launch a generic version of ProstaScint?
A direct generic launch would be commercially unlikely. A competitor would face clinical-performance, manufacturing, radiopharmacy, and regulatory barriers even if historical patent protection had expired.
Did ProstaScint have biosimilar competition?
No. ProstaScint was a discontinued diagnostic radiopharmaceutical rather than a currently marketed therapeutic biologic with an active biosimilar market.
References
-
U.S. Food and Drug Administration. (1996). ProstaScint kit for the preparation of indium In-111 capromab pendetide: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: ProstaScint, NDA 020642. FDA.
-
Cytogen Corporation. (2009-2010). Annual reports and Form 10-K filings. U.S. Securities and Exchange Commission.
